Inactive Instrument

All News W WORL

Equities

Pharmos Corp. Designates Eric Fangmann as Acting President and Acting Chief Financial Officer	03/13/03	CI
Pharmos Corp. Announces Management Changes	18/12/18	CI
Pharmos Corp. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2012	30/12/30	CI
Pharmos Corp. Announces Successfully Completion of Proof-Of-Concept Clinical Trial Using its Compound Levotofisopam to Treat Patients with Hyperuricemia and Gout	18/12/18	CI
Pharmos Corp. Announces Unaudited Consolidated Financial Results for the First Quarter Ended March 31, 2012	16/12/16	CI
Pharmos Corp. Provides Update on Ongoing Clinical Trial of Levotofisopam for the Treatment of Gout	06/12/06	CI
Pharmos Corp. Announces Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2011	18/12/18	CI

No results for this search